Santarus, Inc. (NASDAQ: SNTS) today announced that it will release fourth quarter and full year 2011 financial results after market close on Monday, March 5, 2012. Santarus management will host an investment-community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss the financial results and provide a corporate update. Individuals interested in participating in the conference call may do so by dialing (888) 803-8275 for domestic callers, or (706) 643-7736 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company’s website at www.santarus.com. A webcast replay will be available on the Santarus website for 14 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (855) 859-2056 for domestic callers, or (404) 537-3406 for international callers, and entering reservation code: 47532384. About Santarus Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company’s current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes, and on FENOGLIDE® (fenofibrate) tablets, which is indicated as an adjunct to diet to reduce high cholesterol. Santarus has a diverse product development pipeline. In December 2011, the company submitted an NDA to the FDA for UCERIS ™ (budesonide) tablets for induction of remission of active mild to moderate ulcerative colitis. The pipeline also includes two late-stage investigational drugs: RHUCIN ® (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema and rifamycin SV MMX ® for treatment of travelers’ diarrhea, both of which are being evaluated in Phase III clinical studies. In addition, the company’s investigational monoclonal antibody, SAN-300, is being evaluated in a Phase I clinical program. More information about Santarus is available at www.santarus.com. Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans or objectives will be achieved.Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarus' businesses, including, without limitation: difficulties or delays in development, testing, manufacturing and marketing of, and obtaining and maintaining regulatory approvals for, Santarus' products; and other risks detailed in prior press releases as well as in public periodic filings with the Securities and Exchange Commission.You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.Santarus®, FENOGLIDE® and UCERIS™ are trademarks of Santarus, Inc.GLUMETZA® is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc.CYCLOSET® is a trademark of VeroScience LLC.MMX® is a trademark of Cosmo Technologies Limited. RHUCIN® is a trademark of Pharming Group NV.